

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

INSIDE INFORMATION
FORECAST OF THE GROUP'S ANNUAL REVENUE FOR THE FIRST
YEAR OF COMMERCIALIZATION

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) in accordance with Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that for the year ended December 31, 2025 (the “**Reporting Period**”), the Group expects to achieve revenue of approximately RMB90 million to RMB92 million, other income and gains of approximately RMB15 million to RMB18 million, amounting to a total of approximately RMB105 million to RMB110 million.

The Group achieved considerable revenue in its first year of commercialization, which is primarily attributable to the following factors during the Reporting Period:

1. The Group's transcatheter aortic valve replacement system, Ken-Valve, delivered solid revenue in its first year of commercialization. Indicated for aortic regurgitation or combined with aortic stenosis, the advantages of Ken-Valve's design and clinical performance have enabled the rapid adoption and penetration of the therapy across multi-tier medical institutions.
2. The Group's multiple structural heart interventional products have been applied in paid clinical implantations overseas. Their investigational results and clinical application strengths have earned high recognition from key opinion leaders and experts across continents, addressing the vast long-unmet clinical needs in structural heart disease globally.

The Group will continue to advance the development of multiple product portfolio and further deepen its international strategic layout in 2026 to achieve sustainable revenue growth; and will continuously enhance management efficiency and reduce operating costs in production, supply chain, marketing and sales, and operational management to achieve long-term strategic development goals.

As of the date of this announcement, the Company is still in the process of preparing and finalizing the annual results of the Group for the Reporting Period. The above operating information is preliminary unaudited information and has not been reviewed, confirmed or audited by the auditors of the Company, or reviewed by the audit committee of the Board. It is for investors' reference only, and shall not be considered as a measure or indicator of the future financial performance of the Group. Shareholders and potential investors are advised to read carefully the results announcement of the Company in respect of the Group for the Reporting Period, which is expected to be released in March 2026 in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei

Executive Director and Chief Executive Officer

Hong Kong, January 26, 2026

As at the date of this announcement, the executive Director of the Company is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.